Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
Hyun Ae Jung, Chul Won Jung, Jun Ho Jang
Korean J Intern Med. 2021;36(2):413-423. Published online 2020 Oct 23 DOI: https://doi.org/10.3904/kjim.2019.385
Citations to this article as recorded by 
Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission
Francesca Tiso, Konnie M. Hebeda, Saskia M.C. Langemeijer, Aniek O. de Graaf, Joost H.A. Martens, Thessa N. Koorenhof-Scheele, Ruth Knops, Leonie I. Kroeze, Bert A. van der Reijden, Joop H. Jansen
Pathobiology.2024; 91(5): 326. CrossRef
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
Hannah Beird, C. Cameron Yin, Joseph D. Khoury, Sherry Pierce, Hussein A. Abbas, Li Zhao, Anna Skwarska, Muzaffar Qazilbash, Marina Konopleva, P. Andrew Futreal, Naveen Pemmaraju
Blood Advances.2023; 7(10): 2000. CrossRef
The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
Alicja Pawlak, Kinga Chybicka, Ewa Zioło, Leon Strządała, Wojciech Kałas
Cancers.2022; 14(6): 1530. CrossRef
Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication
Abdulla Watad, Mark Kacar, Nicola Luigi Bragazzi, Qiao Zhou, Miriam Jassam, Jan Taylor, Eve Roman, Alexandra Smith, Richard A. Jones, Howard Amital, Catherine Cargo, Dennis McGonagle, Sinisa Savic
Frontiers in Immunology.2021;[Epub] CrossRef
High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies
Ziqi Wan, Bing Han
Aging.2021; 13(8): 11120. CrossRef